全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 1202757-89-8 |
|---|---|---|---|
| 分子式 | C22H22FN5O3 | 纯度 | ＞98% |
| 分子量 | 423.44 | 货号 | abs810354 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | is a covalent, highly selective, orally | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
AVL-292 1202757-89-8
| 产品描述 | |
| 描述 | AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
| 纯度 | >98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | CC-292; AVL292; AVL-292; AVL 292;Spebrutinib |
| 外观 | Powder |
| 可溶性/溶解性 | DMSO 85 mg/mL (200.73 mM) |
| 生物活性 | |
| 靶点 | BTK |
| In vitro(体外研究) | AVL-292 exhibits dose-dependent inhibition of Btk with EC50 of 8 nM and downstream BCR signaling components in Ramos cells. AVL-292, by inhibiting BTK activities, further inhibits B cell proliferation with EC50 of 3 nM. |
| In vivo(体内研究) | In a collagen-induced arthritis mouse model, AVL-292 (3- 30 mg/kg, p.o.) dose-dependently inhibits the clinical signs of inflammatory disease, including reduction in joint and paw swelling and visible redness of the affected paws. |
| 研究领域 | |
| 研究领域 | ImmunologyInnate ImmunityTLR Signaling Signal TransductionProtein PhosphorylationTyrosine KinasesOther Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：